Altre lingue Kiora Pharmaceuticals, Inc.

Azioni

KPRX

US49721T5074

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/06/2024			Variaz. 5gg	Var. 1 gen.
4,17 ^USD	+2,21%		-2,80%	-11,31%

25/06	Kiora Pharmaceuticals nomina Roger A. Goldberg nel suo Comitato Scientifico Consultivo	CI
10/05	Kiora Pharmaceuticals, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Kiora Pharmaceuticals Appoints Roger A. Goldberg to its Scientific Advisory Board	25/06
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences	20/05
Kiora Pharmaceuticals Reports First Quarter Results, Update on Pipeline of Drugs Targeting Retinal Disease	13/05
Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M	10/05
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease	10/05
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference	08/05
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa	06/05
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases, Approval Granted to Initiate Clinical Validation Study	12/04
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study	11/04
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences	05/04
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting	28/03
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases	25/03
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye	08/03
Kiora Pharmaceuticals Grants License to Thea Open for Molecular Photoswitch Product - Shares Surge	01/02
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million	01/02
Kiora Pharmaceuticals, Inc. announced that it expects to receive $42.274525 million in funding from ADAR1 Capital Management, LLC, Nantahala Capital Management, LLC, Rosalind Advisors, Inc., Stonepine Capital Management LLC, Velan Capital Partners LP	01/02
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties	31/01
Kiora Pharmaceuticals, Inc. Enters into an Exclusive License and Development Agreement with Théa Open Innovation SAS	31/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Kiora Pharmaceuticals, Inc.

Azioni

KPRX

US49721T5074

Altre lingue

Filtri